Pfizer’s Avagliano Joins G1 Therapeutics as Chief Business Officer

Posted by |2019-07-31T10:39:22-07:00July 31st, 2019|

G1 Therapeutics (NASDAQ: GTHX) has tapped Mark Avagliano to become its chief business officer. Avagliano joins the Research Triangle Park, NC-based cancer drug developer from Pfizer (NYSE: PFE), where he was vice president of corporate development. Lead G1 drug candidate trilaciclib, which has been tested in small-cell lung cancer and metastatic triple-negative breast cancer, is […]

Illumina Cuts Forecasts As Consumer Tests, Genomics Initiatives Lag

Posted by |2019-07-30T14:26:11-07:00July 30th, 2019|

About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. It exceeded that goal, with revenue rising 21 percent to $3.33 billion by the end of 2018. It’s a different financial story this summer. On Monday, Illumina (NASDAQ: ILMN) informed the markets that it […]

Turning Point Therapeutics Taps Investment Banker Yi Larson as CFO

Posted by |2019-07-29T12:19:04-07:00July 29th, 2019|

Turning Point Therapeutics (NASDAQ: TPTX) has hired one of the investment bankers who guided it to the public markets earlier this year as its chief financial officer. Yi Larson, a managing director at New York-based investment bank Goldman Sachs (NYSE: GS), where she has worked for about 12 years, most recently led its healthcare investment […]

Verb Surgical Taps Kurt Azarbarzin for CEO Role

Posted by |2019-07-29T03:30:06-07:00July 26th, 2019|

Surgical robot developer Verb Surgical has appointed Kurt Azarbarzin to serve as its new CEO. He joins Mountain View, CA-based Verb from CONMED, where he was chief technology officer. Azarbarzin’s experience also includes senior roles at SurgiQuest, Tyco Healthcare, and Covidien. Azarbarzin succeeds former Verb CEO Scott Huennekens, who left the company at the end […]

Obsidian Appoints Stehman-Breen Chief Development Officer

Posted by |2019-07-25T08:16:13-07:00July 25th, 2019|

Catherine Stehman-Breen is joining Obsidian Therapeutics as chief development officer. She was most recently an entrepreneur in residence at Atlas Venture, where she held the chief medical officer positions at Dyne Therapeutics and Disarm Therapeutics, two of the venture capital firm’s portfolio companies. Stehman-Breen’s experience also includes posts at Sarepta Therapeutics (NASDAQ: SRPT), Regeneron Pharmaceuticals […]

Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck

Posted by |2019-07-24T14:10:24-07:00July 24th, 2019|

Bristol-Myers Squibb (NYSE: BMY) this afternoon revealed yet another setback for its cancer immunotherapy nivolumab (Opdivo) in lung cancer, boosting the outlook for rival Merck. The New York pharma giant said that a regimen of nivolumab (Opdivo) and chemotherapy failed to extend the lives of non-squamous, non-small cell lung cancer patients compared to chemo alone […]

Proteostasis Names Gilmartin Chief Medical Officer, Succeeding Lee

Posted by |2019-07-23T09:06:01-07:00July 23rd, 2019|

Geoffrey Gilmartin is taking on a new role at Proteostasis Therapeutics (NASDAQ: PTI) as its chief medical officer. He will succeed Po-Shun Lee, who will become a consultant to the Boston-based cystic fibrosis (CF) drug developer after serving in the CMO role for the past four years. Gilmartin joined Proteostasis in 2016 as chief development […]

Acadia Pharmaceuticals Drug Fails in Late-Stage Schizophrenia Trial

Posted by |2019-07-22T15:20:55-07:00July 22nd, 2019|

Acadia Pharmaceuticals’ treatment for Parkinson’s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven’t fully responded to existing therapies. The company announced the trial failure Monday after market close. Acadia (NASDAQ: ACAD) shares dropped about 4 percent on the news in after-hours trading, falling from […]

Spine-Surgery Medtech Startup Carlsmed Merges With Imaging Company

Posted by |2019-07-22T03:30:05-07:00July 19th, 2019|

Carlsmed, a San Diego-based medical technology company that’s developing personalized spinal implants, has merged with Precisive Surgical, a spine imaging system startup in Seattle. The combined company, which will operate in San Diego under the Carlsmed name, aims to create a platform that will use imaging recognition technology, 3D printing, and other tools to allow […]

Kronos Bio Reels In $105M for Drugs That Hit “Undruggable” Targets

Posted by |2019-07-18T08:54:02-07:00July 18th, 2019|

Kronos Bio has raised $105 million in financing to develop therapies intended to target disease-causing proteins that have so far eluded the best efforts of drug hunters. The Series A round of funding announced Thursday was led by Vida Ventures and Omega Funds. Drugs typically work by either binding to a target site on a […]

Pandion Therapeutics Picks Corvidia’s Rahul Kakkar for CEO

Posted by |2019-07-17T14:41:00-07:00July 17th, 2019|

Rahul Kakkar is the new CEO of Pandion Therapeutics. He has also joined the Cambridge, MA, company’s board of directors. Kakkar was most recently chief medical officer and chief strategy officer of Corvidia Therapeutics. He succeeds Pandion founder Anthony Coyle, who is leaving the company. In other moves, Jo Viney, a founder and chief scientific […]

San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak

Posted by |2019-07-16T21:01:07-07:00July 16th, 2019|

San Antonio — Ah, to be able to regrow a missing limb like a slimy salamander—a trick long dreamed of by youngsters and scientists alike. Research into such regenerative abilities has increasingly excited the scientific community during the past 30 years as it has gained further insight into the potential of the extracellular matrix, a […]

Load More Posts